Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic
Open Access
- 5 June 2024
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (1) , 577-586
Abstract
Purpose: Our prospective international survey evaluated the impact of the early phase of the COVID-19 pandemic on the management gynaecological malignancies from the multidisciplinary physicians’ perspective with particular focus on clinical infrastructures and trial participation. Methods: Our survey consisted of 53 COVID-related questions. It was sent to healthcare professionals in gynaecological oncology centres across Europe and Pan-Arabian region via the study groups and gynaecological societies from April 2020 to October 2020. All healthcare professionals treating gynaecological cancers were able to participate in our survey. Results: A total of 255 answers were collected from 30 countries. The majority (73%) of participants were gynaecological oncologists from university hospitals (71%) with at least an Intensive Care Unit with cardiopulmonary support available at their institutions. Most institutions continued to perform elective surgeries only for oncological cases (98%). Patients had to wait on average 2 weeks longer for their surgery appointments compared to previous years (range 0–12 weeks). Most cases that were prioritised for surgical intervention across all gynaecological tumours were early-stage disease (74%), primary situation (61%) and good ECOG status (63%). The radicality of surgery did not change in the majority of cases (78%) across all tumour types. During the pandemic, only 38% of clinicians stated they would start a new clinical trial. Almost half of the participants stated the pandemic negatively impacted the financial structure and support for clinical trials. Approximately 20% of clinicians did not feel well-informed regarding clinical algorithm for COVID-19 patients throughout the pandemic. Thirty percent stated that they are currently having trouble in providing adequate medical care due to staff shortage. Conclusion: Despite well-established guidelines, pandemic clearly affected clinical research and patientcare. Our survey underlines the necessity for building robust emergency algorithms tailored to gynaecological oncology to minimise negative impact in crises and to preserve access to clinical trials.Keywords
All Related Versions
Funding Information
- Charité - Universitätsmedizin Berlin
This publication has 33 references indexed in Scilit:
- COVID-19 and gynecological cancer: a review of the published guidelinesInternational Journal of Gynecological Cancer, 2020
- When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 PandemicGynecologic Oncology, 2020
- Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST)The Breast, 2020
- Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisisGynecologic Oncology, 2020
- Gynecological laparoscopic surgery in the shade of COVID-19 pandemicTURKISH JOURNAL OF MEDICAL SCIENCES, 2020
- Change in practice in gynecologic oncology during the COVID-19 pandemic: a social media surveyInternational Journal of Gynecological Cancer, 2020
- NCCN Guidelines Insights: Cervical Cancer, Version 1.2020Journal of the National Comprehensive Cancer Network, 2020
- Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemicNature Reviews Clinical Oncology, 2020
- Gynecologic oncology at the time of COVID-19 outbreakJournal of Gynecologic Oncology, 2020
- European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer SurgeryInternational Journal of Gynecological Cancer, 2016